ASX:ANR

Email Alerts for:
ASX:ANR

Anatara Lifesciences (ASX:ANR) - gastrointestinal health developer

30 Apr 2019 - Anatara Lifesciences Limited (ASX:ANR) CEO, Steven Lydeamore talks about the company's clinical studies program and its lead Gastrointestinal Reprogramming Product (G…

Anatara LifeSciences (ASX:ANR) Presentation, FNN Investor Event, April 2019, Sydney

30 Apr 2019 - Anatara Lifesciences Limited (ASX:ANR) CEO, Steven Lydeamore presents on the company's lead Gastrointestinal Reprogramming Product (GaRP) for Irritable Bowel Syndrome…

Anatara Lifesciences receives $840k R&D incentive

06 Jun 2017 - Anatara Lifesciences Ltd (ASX:ANR) has received a $840,000 Federal Government R&D tax Incentive.

Anatara completes overdosing tests on piglets

08 Sep 2016 - Anatara Lifesciences (ASX:ANR) completes tests on piglets for its lead product, Detach.

Anatara Lifesciences: Presentation, CEO Sessions Sydney

30 Jun 2016 - Anatara Lifesciences (ASX:ANR) Chairman Dr Mel Bridges presents at the ASX CEO Sessions in Sydney

Anatara Lifesciences (ASX:ANR) discusses Detach

30 Jun 2016 - Anatara Lifesciences (ASX:ANR) Chairman, Dr Mel Bridges, discusses Detatch, a new natural treatment for scour and gastrointestinal disease.

Anatara terminates efficacy trial on pigs

23 Jun 2016 - Anatara Lifesciences Ltd (ASX:ANR) terminates third efficacy study in Australia for its lead product, Detach.

Anatara progresses with launching ‘Detach’

16 Jun 2016 - Anatara commences two new animal trials, and expects to launch its lead product, Detach, in 2017.

Midday: Aus shares follow Wall St lower

03 Jul 2015 - Aus shares follow Wall St lower. New Zealand based Orion Health Group Limited (ASX:OHE) secures two new strategic deals in Vietnam to build its market presence in Asi…